Chembio Diagnostic Systems, Inc.

Chembio Diagnostics, Inc. develops, manufactures, licenses and markets proprietary rapid diagnostic tests in the growing $10 billion point-of-care testing market. Chembio's three FDA PMA-approved, CLIA-waived, rapid HIV tests are marketed in the US: SURE CHECK® HIV 1/2, HIV 1/2 STAT-PAK® and DPP® HIV 1/2 assays. Chembio markets its DPP® HIV-Syphilis assay and other rapid tests internationally to government and donor-funded programs directly and through distributors. Chembio has developed a patented point-of-care test platform technology, the Dual Path Platform (DPP®) technology, which has advantages over lateral-flow technologies when it comes to multiplexing and working with challenging matrices. This technology provides Chembio with a significant pipeline of business opportunities for the development and manufacture of new products. Headquartered in Medford, NY, with approximately 150 employees, Chembio is licensed by the U.S. Food and Drug Administration (FDA) as well as the U. S. Department of Agriculture (USDA), and is certified for the global market under the International Standards Organization (ISO) directive 13.485.